Gene therapy injection aims to halt vision loss in stargardt patients
NCT ID NCT07241169
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a gene therapy called ZVS106e for Stargardt disease, a genetic condition that causes vision loss. Nine participants will receive a single injection of the drug under their retina. The main goal is to check safety over 52 weeks, not yet to prove it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ZVS106e (a gene replacement drug delivered via a harmless virus into the eye)
- What this could lead to
- If it works, this could point toward a treatment that slows or stops vision loss in people with Stargardt disease caused by ABCA4 mutations.
- What could go wrong
- This is a very early, small trial (9 people) focused on safety, not effectiveness. The treatment involves eye surgery, which carries risks like infection or retinal damage. Success is far from guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY RETINAL DEGENERATION CAUSED BY ABCA4 BIALLELIC MUTATIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University Third Hospital
RECRUITINGBeijing, Beijing Municipality, China
-
Zhongshan Ophthalmic Center, Sun Yat-sen University
NOT_YET_RECRUITINGGuangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.